Furthermore, mutations in SRSF2 and SF3B1, which also contained MGO modifications in this study, are observed in 5–75% of patients with various myeloid neoplasms, particularly chronic myelomonocytic leukemia and refractory anaemia with ring sideroblasts [40]. Here, SRSF2 is linked to chronic myelomonocytic leukemia.